106 related articles for article (PubMed ID: 7808966)
21. [Special clinical and follow-up aspects of invasive lobular breast cancer].
Mitze M; Meyer F; Goepel E; Kleinkauf-Houcken A; Jonat W
Geburtshilfe Frauenheilkd; 1991 Dec; 51(12):973-9. PubMed ID: 1794684
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical localization of metallothionein in endometrial lesions.
Ioachim EE; Kitsiou E; Carassavoglou C; Stefanaki S; Agnantis NJ
J Pathol; 2000 Jul; 191(3):269-73. PubMed ID: 10878548
[TBL] [Abstract][Full Text] [Related]
23. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
25. Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses.
Muramatsu Y; Hasegawa Y; Fukano H; Ogawa T; Namuba M; Mouri K; Fujimoto Y; Matsuura H; Takai Y; Mori M
Anticancer Res; 2000; 20(1A):257-64. PubMed ID: 10769664
[TBL] [Abstract][Full Text] [Related]
26. Correlation of intensity of MT-I/II expression with Ki-67 and MCM-2 proteins in invasive ductal breast carcinoma.
Wojnar A; Pula B; Piotrowska A; Jethon A; Kujawa K; Kobierzycki C; Rys J; Podhorska-Okolow M; Dziegiel P
Anticancer Res; 2011 Sep; 31(9):3027-33. PubMed ID: 21868554
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions.
Bier B; Douglas-Jones A; Tötsch M; Dockhorn-Dworniczak B; Böcker W; Jasani B; Schmid KW
Breast Cancer Res Treat; 1994; 30(3):213-21. PubMed ID: 7981441
[TBL] [Abstract][Full Text] [Related]
28. [Effect of the proliferation rate on the course of node negative breast carcinoma].
Mitze M; Weikel W; Brumm C; Lippold R; Knapstein PG
Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):299-305. PubMed ID: 7657137
[TBL] [Abstract][Full Text] [Related]
29. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
30. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
32. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up.
Reed W; Bøhler PJ; Sandstad B; Nesland JM
Breast J; 2004; 10(3):174-80. PubMed ID: 15125740
[TBL] [Abstract][Full Text] [Related]
33. Expression of E-cadherin and catenins in invasive mammary carcinomas.
Zschiesche W; Schönborn I; Behrens J; Herrenknecht K; Hartveit F; Lilleng P; Birchmeier W
Anticancer Res; 1997; 17(1B):561-7. PubMed ID: 9066580
[TBL] [Abstract][Full Text] [Related]
34. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
35. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
Pirinen R; Lipponen P; Syrjänen K
Anticancer Res; 1995; 15(6B):2835-40. PubMed ID: 8669874
[TBL] [Abstract][Full Text] [Related]
36. Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast.
Heatley MK; Ewings P; Odling Smee W; Maxwell P; Toner PG
Pathology; 2002 Jun; 34(3):230-2. PubMed ID: 12109782
[TBL] [Abstract][Full Text] [Related]
37. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
[TBL] [Abstract][Full Text] [Related]
38. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
[TBL] [Abstract][Full Text] [Related]
39. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
